Intelligent Bio shares surge 30.97% premarket after reporting 48% Y/Y revenue growth in Q2 2026 driven by expanding customer base and product growth.

Intelligent Bio Solutions Inc. (INBS) surged 30.97% in premarket trading following the announcement of preliminary, unaudited revenue results for fiscal Q2 2026. The company expects a 48% year-over-year revenue increase, with total revenue surpassing $2 million, driven by a 104% rise in reader sales and 33% growth in cartridge sales. Management attributed the performance to an expanding customer base and the success of its razor-razorblade business model, where reader placements generate recurring cartridge revenue. CEO Harry Simeonidis highlighted momentum across all product categories and confidence in capturing market share, reinforcing the stock’s upward movement. The premarket rally reflects investor optimism over the company’s commercial strategy and long-term revenue potential.